OGN vs PODD · P/E 3.4, rev $6.40B vs P/E 34, rev $2.07B
Organon & Co (OGN) versus Insulet Corporation (PODD) — a side-by-side from cached financials, not a winner call.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Insulet Corporation (PODD) is a medical devices company listed on NASDAQ.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Latest reported PODD revenue for 2024-12-31 was $2.07B. Net income was $418.3M. Revenue was up 22.1% from 2023-12-31 to 2024-12-31. PODD currently screens at market cap $9.94B and trailing P/E 33.5.
OGN currently screens at market cap $2.52B and trailing P/E 3.4. PODD currently screens at market cap $9.94B and trailing P/E 33.5.
Not investment advice. Open the OGN and PODD stock pages for the full models.
Not investment advice.